Results 31 to 40 of about 20,954 (250)

Long-Term Treatment of Unresectable Pseudomyxoma Peritonei with Multiple Treatments of Intratumoural Bromelain and Acetylcysteine (BromAc®): A Case Report

Case Reports in Oncology, 2023
Pseudomyxoma peritonei is a rare peritoneal malignancy characterized by the progressive accumulation of mucinous material and tumour within the abdomen and pelvis.
Jessica Yang, D. Glenn, S. Lodh, Sarah Valle, D. Morris   +4 more
semanticscholar   +1 more source

Pseudomyxoma peritonei

BJOG: An International Journal of Obstetrics & Gynaecology, 1996
Pseudomyxoma peritonei is a clinical entity that has lead to much confusion about its etiology, clinical manifestations, treatment, and prognosis. Pseudomyxoma peritonei is currently defined as a grade I mucinous adenocarcinoma that arises from a primary appendiceal adenoma. The clinical entity is defined by a redistribution phenomenon. This means that
K, GEORGIEV, K, SERAFIMOV
  +7 more sources

The Cancer Diaspora: A Rare Case of Pseudomyxoma Peritonei of Appendiceal Origin

Journal of Investigative Medicine High Impact Case Reports, 2023
Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by widespread mucinous implants in the peritoneal cavity. Commonly seen in females in their 50s, PMP typically originates from ruptured appendiceal mucoceles that find refuge in the ...
Lefika Bathobakae MD, MPH, Sacide S. Ozgur MD, Mohita Jariwala BA, Jaydev Kesrani MD, Shajla Ajas MD, Mehandar Kumar MD, Amer Akmal MD   +6 more
doaj   +1 more source

Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines

Orphanet Journal of Rare Diseases, 2021
Background Pseudomyxoma peritonei (PMP) is a clinical malignant syndrome mainly originating from the appendix, with an incidence of 2–4 per million people. As a rare disease, an early and accurate diagnosis of PMP is difficult. It was not until the 1980s
Yulin Lin, Dachong Xu, Xin-Bao Li, Fengcai Yan, Hong-Bin Xu, Zheng Peng, Yan Li   +6 more
semanticscholar   +1 more source

Survival prediction by Bayesian network modeling for pseudomyxoma peritonei after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy

Cancer Medicine, 2022
To establish a survival prognostic model for pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) based on Bayesian network (BN).
Xin Zhao, Xin-Bao Li, Yulin Lin, R. Ma, Ying Zhang, Dazhao Xu, Yan Li   +6 more
semanticscholar   +1 more source

Pseudomyxoma peritonei – two novel orthotopic mouse models portray the PMCA-I histopathologic subtype [PDF]

, 2007
Background Pseudomyxoma peritonei (PMP) is a rare malignant disease, most commonly originating from appendiceal lesions and characterized by accumulation of mucinous tumor tissue in the peritoneal cavity.
Kjersti Flatmark, Wenche Reed, Thomas Halvorsen, Olaf Sørensen, Johan N Wiig, Stein G Larsen, Øystein Fodstad, Karl-Erik Giercksky, BM Ronnett, C Guerrieri, M Cuatrecasas, C Szych, RH Young, RM Smeenk, TJ Miner, BM Ronnett, TD Yan, V Maheshwari, RF Bradley, F Alexander-Sefre, R Bibi, DC Brown, M Yakushiji   +22 more
core   +2 more sources

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +4 more sources

Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Digestive and Liver Disease, 2021
INTRODUCTION This document is a summary of the French Intergroup guidelines regarding the management of appendicular epithelial tumors (AT) and pseudomyxoma peritonei (PMP) published in March 2020, available on the website of the French Society of ...
J. Delhorme, L. Villeneuve, O. Bouché, G. Avérous, A. Dohan, J. Gornet, B. You, F. Bibeau, P. Dartigues, C. Eveno, J. Fontaine, V. Képénékian, M. Pocard, P. Rousset, F. Quénet, P. Mariani, O. Glehen, D. Goéré   +17 more
semanticscholar   +1 more source

Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei

ANZ journal of surgery, 2022
Pseudomyxoma peritonei (PMP) is a clinically malignant tumour syndrome mainly derived from mucin‐producing appendiceal tumours. This study aimed to explore the effect of preoperative systemic chemotherapy (PSC) before cytoreductive surgery (CRS) plus ...
R. Ma, D. Lu, Shilin Xue, Xi-wen Fan, X. Zhai, Chong Wang, Hongbin Xu, Sha-Sha Pang   +7 more
semanticscholar   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source